Veracyte Retained Earnings vs Accounts Payable Analysis

VCYT Stock

USD 20.65 0.76 3.55%

Veracyte financial indicator trend analysis is much more than just breaking down Veracyte prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Veracyte is a good investment. Please check the relationship between Veracyte Retained Earnings and its Accounts Payable accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

Retained Earnings vs Accounts Payable

Retained Earnings vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Veracyte Retained Earnings account and Accounts Payable. At this time, the significance of the direction appears to have pay attention.

The correlation between Veracyte's Retained Earnings and Accounts Payable is -0.75. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Veracyte, assuming nothing else is changed. The correlation between historical values of Veracyte's Retained Earnings and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Veracyte are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Retained Earnings i.e., Veracyte's Retained Earnings and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.75

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Accounts Payable

An accounting item on the balance sheet that represents Veracyte obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Veracyte are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Veracyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Veracyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.At this time, Veracyte's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 392.7 K in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	227.0M	236.0M	235.2M	247.0M
Cost Of Revenue	74.4M	101.6M	137.9M	144.8M

Total Operating Expenses Cost Of Revenue

Veracyte fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment
Total Assets		0.98	0.98	1.0	0.76	0.96	-0.68	-0.88	0.9	0.61	0.98	-0.5	0.3	0.63	0.98	0.9	0.84	0.49	0.95	0.84	0.99	0.94	0.88	0.72	0.8	0.96
Other Current Liab	0.98		1.0	0.98	0.74	0.95	-0.58	-0.85	0.95	0.51	0.99	-0.51	0.2	0.54	0.96	0.89	0.81	0.51	0.96	0.84	0.97	0.96	0.88	0.65	0.79	0.97
Total Current Liabilities	0.98	1.0		0.98	0.73	0.94	-0.57	-0.85	0.96	0.5	0.99	-0.51	0.18	0.53	0.96	0.88	0.8	0.49	0.96	0.84	0.97	0.95	0.88	0.64	0.78	0.97
Total Stockholder Equity	1.0	0.98	0.98		0.75	0.96	-0.68	-0.87	0.9	0.61	0.98	-0.5	0.3	0.63	0.97	0.89	0.84	0.48	0.94	0.84	0.99	0.93	0.88	0.73	0.8	0.96
Other Liab	0.76	0.74	0.73	0.75		0.81	-0.7	-0.73	0.61	0.74	0.7	-0.56	0.5	0.74	0.76	0.77	0.84	0.65	0.66	0.83	0.76	0.76	0.56	0.81	0.84	0.71
Property Plant And Equipment Net	0.96	0.95	0.94	0.96	0.81		-0.71	-0.94	0.85	0.66	0.93	-0.44	0.34	0.68	0.98	0.96	0.9	0.63	0.96	0.81	0.98	0.96	0.88	0.77	0.88	0.96
Net Debt	-0.68	-0.58	-0.57	-0.68	-0.7	-0.71		0.69	-0.48	-0.97	-0.54	0.11	-0.7	-0.97	-0.68	-0.77	-0.71	-0.41	-0.61	-0.46	-0.69	-0.59	-0.57	-0.94	-0.74	-0.56
Retained Earnings	-0.88	-0.85	-0.85	-0.87	-0.73	-0.94	0.69		-0.75	-0.65	-0.83	0.27	-0.34	-0.67	-0.94	-0.95	-0.92	-0.72	-0.91	-0.68	-0.94	-0.92	-0.86	-0.75	-0.87	-0.91
Accounts Payable	0.9	0.95	0.96	0.9	0.61	0.85	-0.48	-0.75		0.4	0.92	-0.43	0.07	0.42	0.87	0.82	0.68	0.42	0.92	0.76	0.89	0.9	0.85	0.52	0.7	0.91
Cash	0.61	0.51	0.5	0.61	0.74	0.66	-0.97	-0.65	0.4		0.46	-0.18	0.77	1.0	0.62	0.73	0.75	0.49	0.53	0.49	0.63	0.54	0.45	0.98	0.79	0.49
Non Current Assets Total	0.98	0.99	0.99	0.98	0.7	0.93	-0.54	-0.83	0.92	0.46		-0.54	0.17	0.49	0.95	0.84	0.79	0.45	0.93	0.86	0.96	0.93	0.87	0.6	0.73	0.96
Non Currrent Assets Other	-0.5	-0.51	-0.51	-0.5	-0.56	-0.44	0.11	0.27	-0.43	-0.18	-0.54		-0.37	-0.21	-0.42	-0.29	-0.49	-0.15	-0.3	-0.84	-0.44	-0.4	-0.08	-0.31	-0.45	-0.39
Other Assets	0.3	0.2	0.18	0.3	0.5	0.34	-0.7	-0.34	0.07	0.77	0.17	-0.37		0.79	0.29	0.38	0.53	0.21	0.16	0.35	0.32	0.19	-0.03	0.75	0.54	0.14
Cash And Short Term Investments	0.63	0.54	0.53	0.63	0.74	0.68	-0.97	-0.67	0.42	1.0	0.49	-0.21	0.79		0.64	0.74	0.77	0.48	0.55	0.51	0.65	0.56	0.46	0.99	0.81	0.51
Net Receivables	0.98	0.96	0.96	0.97	0.76	0.98	-0.68	-0.94	0.87	0.62	0.95	-0.42	0.29	0.64		0.95	0.89	0.62	0.97	0.8	0.99	0.97	0.9	0.74	0.85	0.97
Common Stock Total Equity	0.9	0.89	0.88	0.89	0.77	0.96	-0.77	-0.95	0.82	0.73	0.84	-0.29	0.38	0.74	0.95		0.88	0.72	0.93	0.7	0.94	0.95	0.86	0.81	0.92	0.91
Common Stock Shares Outstanding	0.84	0.81	0.8	0.84	0.84	0.9	-0.71	-0.92	0.68	0.75	0.79	-0.49	0.53	0.77	0.89	0.88		0.7	0.81	0.81	0.89	0.83	0.69	0.86	0.95	0.81
Non Current Liabilities Total	0.49	0.51	0.49	0.48	0.65	0.63	-0.41	-0.72	0.42	0.49	0.45	-0.15	0.21	0.48	0.62	0.72	0.7		0.57	0.49	0.57	0.71	0.53	0.55	0.77	0.6
Inventory	0.95	0.96	0.96	0.94	0.66	0.96	-0.61	-0.91	0.92	0.53	0.93	-0.3	0.16	0.55	0.97	0.93	0.81	0.57		0.7	0.96	0.96	0.95	0.65	0.8	0.97
Other Current Assets	0.84	0.84	0.84	0.84	0.83	0.81	-0.46	-0.68	0.76	0.49	0.86	-0.84	0.35	0.51	0.8	0.7	0.81	0.49	0.7		0.81	0.79	0.56	0.63	0.78	0.78
Other Stockholder Equity	0.99	0.97	0.97	0.99	0.76	0.98	-0.69	-0.94	0.89	0.63	0.96	-0.44	0.32	0.65	0.99	0.94	0.89	0.57	0.96	0.81		0.96	0.9	0.75	0.84	0.97
Total Liab	0.94	0.96	0.95	0.93	0.76	0.96	-0.59	-0.92	0.9	0.54	0.93	-0.4	0.19	0.56	0.97	0.95	0.83	0.71	0.96	0.79	0.96		0.9	0.66	0.84	0.98
Property Plant And Equipment Gross	0.88	0.88	0.88	0.88	0.56	0.88	-0.57	-0.86	0.85	0.45	0.87	-0.08	-0.03	0.46	0.9	0.86	0.69	0.53	0.95	0.56	0.9	0.9		0.54	0.65	0.94
Total Current Assets	0.72	0.65	0.64	0.73	0.81	0.77	-0.94	-0.75	0.52	0.98	0.6	-0.31	0.75	0.99	0.74	0.81	0.86	0.55	0.65	0.63	0.75	0.66	0.54		0.88	0.62
Common Stock	0.8	0.79	0.78	0.8	0.84	0.88	-0.74	-0.87	0.7	0.79	0.73	-0.45	0.54	0.81	0.85	0.92	0.95	0.77	0.8	0.78	0.84	0.84	0.65	0.88		0.78
Property Plant Equipment	0.96	0.97	0.97	0.96	0.71	0.96	-0.56	-0.91	0.91	0.49	0.96	-0.39	0.14	0.51	0.97	0.91	0.81	0.6	0.97	0.78	0.97	0.98	0.94	0.62	0.78

Click cells to compare fundamentals

Veracyte Account Relationship Matchups

Veracyte fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	275.2M	457.2M	1.2B	1.2B	1.1B	1.2B
Other Current Liab	13.7M	11.7M	42.4M	44.0M	41.2M	43.2M
Total Current Liabilities	17.5M	16.8M	64.2M	62.6M	61.2M	64.3M
Total Stockholder Equity	239.5M	421.2M	1.1B	1.1B	1.0B	1.1B
Other Liab	6.1M	8.4M	13.1M	7.6M	8.7M	5.6M
Property Plant And Equipment Net	17.7M	16.8M	31.1M	30.9M	30.9M	32.4M
Net Debt	(145.7M)	(337.0M)	(154.3M)	(139.5M)	(203.8M)	(193.6M)
Retained Earnings	(246.7M)	(281.6M)	(357.2M)	(393.7M)	(468.1M)	(444.7M)
Accounts Payable	2.3M	3.1M	12.4M	11.9M	12.9M	13.6M
Cash	159.3M	349.4M	173.2M	154.2M	216.5M	117.7M
Non Current Assets Total	87.5M	81.5M	944.7M	907.8M	852.2M	894.8M
Non Currrent Assets Other	2.0M	2.0M	(35.1M)	(26.8M)	6.0M	6.3M
Other Assets	2.0M	9.8M	2.9M	6.2M	1.0	0.95
Cash And Short Term Investments	159.3M	349.4M	173.2M	178.9M	216.5M	119.7M
Net Receivables	19.3M	18.5M	41.5M	44.0M	45.1M	47.3M
Common Stock Total Equity	50K	58K	71K	72K	82.8K	86.9K
Common Stock Shares Outstanding	46.1M	53.2M	67.9M	71.5M	72.6M	41.6M
Liabilities And Stockholders Equity	275.2M	457.2M	1.2B	1.2B	1.1B	1.2B
Non Current Liabilities Total	18.3M	19.2M	27.2M	18.6M	32.5M	19.6M
Inventory	6.8M	4.7M	11.2M	14.3M	16.1M	16.9M
Other Current Assets	2.2M	3.2M	17.2M	11.5M	8.0M	4.6M
Other Stockholder Equity	486.1M	702.8M	1.5B	1.5B	1.5B	1.6B
Total Liab	35.8M	35.9M	91.3M	81.2M	93.7M	98.4M
Property Plant And Equipment Gross	17.7M	9.0M	31.1M	30.9M	63.7M	66.9M
Total Current Assets	187.7M	375.7M	243.1M	248.6M	285.6M	148.7M
Accumulated Other Comprehensive Income	(12.0M)	0.0	(15.1M)	(31.3M)	(24.0M)	(22.8M)
Common Stock	50K	58K	71K	72K	73K	42.9K
Property Plant Equipment	8.9M	9.0M	31.1M	30.9M	35.5M	37.3M
Short Long Term Debt Total	13.6M	12.3M	18.9M	14.7M	12.6M	16.3M
Net Tangible Assets	171.7M	358.6M	185.9M	379.3M	436.2M	458.0M
Long Term Debt	25.2M	23.9M	694K	810K	931.5K	884.9K
Retained Earnings Total Equity	(246.7M)	(281.6M)	(357.2M)	(393.7M)	(354.3M)	(372.1M)
Long Term Debt Total	25.2M	23.9M	694K	810K	931.5K	884.9K
Capital Surpluse	486.1M	702.8M	1.5B	1.5B	1.7B	1.8B
Deferred Long Term Liab	4.2M	3.9M	5.6M	4.5M	5.2M	4.3M
Intangible Assets	65.0M	59.9M	202.7M	174.9M	88.6M	66.2M
Short Term Debt	1.4M	1.6M	4.8M	4.1M	5.1M	6.3M

Pair Trading with Veracyte

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Veracyte position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Veracyte will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Veracyte could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Veracyte when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Veracyte - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Veracyte to buy it.

The correlation of Veracyte is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Veracyte moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Veracyte moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Veracyte can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Veracyte Retained Earnings vs Accounts Payable Analysis

Retained Earnings vs Accounts Payable

Retained Earnings vs Accounts Payable Correlation Analysis

Correlation Coefficient

Retained Earnings

Accounts Payable

Veracyte fundamental ratios Correlations

Veracyte Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Veracyte fundamental ratios Accounts

Pair Trading with Veracyte

Additional Tools for Veracyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Cash
Other Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Other Current Liab
Non Current Assets Total	+ 0.99	Total Current Liabilities

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Common Stock Total Equity	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.94	Retained Earnings
Net Receivables	- 0.94	Retained Earnings
Total Current Assets	- 0.94	Net Debt